Catalent - CTLT Stock Forecast, Price & News

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Catalent Price Performance

NYSE:CTLT traded down $1.63 on Tuesday, hitting $109.22. The company had a trading volume of 878,395 shares, compared to its average volume of 1,191,256. Catalent has a 52 week low of $86.34 and a 52 week high of $142.64. The company has a current ratio of 2.89, a quick ratio of 2.25 and a debt-to-equity ratio of 0.90. The stock has a market capitalization of $19.57 billion, a price-to-earnings ratio of 39.57, a PEG ratio of 1.68 and a beta of 1.29. The firm has a 50 day moving average of $107.55 and a two-hundred day moving average of $103.49.

Insider Transactions at Catalent

In other news, CEO Alessandro Maselli sold 816 shares of the stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $106.90, for a total value of $87,230.40. Following the completion of the transaction, the chief executive officer now directly owns 25,083 shares in the company, valued at approximately $2,681,372.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Alessandro Maselli sold 816 shares of the business's stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $106.90, for a total transaction of $87,230.40. Following the sale, the chief executive officer now directly owns 25,083 shares in the company, valued at $2,681,372.70. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Kay A. Schmidt sold 323 shares of the firm's stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $106.90, for a total transaction of $34,528.70. Following the completion of the transaction, the senior vice president now owns 13,455 shares of the company's stock, valued at approximately $1,438,339.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 4,462 shares of company stock worth $476,951. Corporate insiders own 0.53% of the company's stock.